The nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome mediates caspase-1 activation and IL-1β processing and is implicated in autoinflammatory as well as other chronic inflammatory diseases. Recent studies have demonstrated that xanthine oxidoreductase (XOR) inhibition attenuated IL-1β secretion in activated macrophages, but the detailed mechanism of inhibition remains unclear. In this study, we report that febuxostat, an inhibitor of XOR, suppressed NLRP3 inflammasome-mediated IL-1β secretion and cell death by two mechanisms: in a mitochondrial ROS (mitoROS)-dependent and mitoROS-independent manner. MitoROS-independent effects of febuxostat were mediated by an increase of intracellular ATP and improved mitochondrial energetics via the activation of purine salvage pathway. Our findings suggest that cellular bioenergetics are important in regulating NLRP3 activation, and XOR inhibition may be clinically relevant in NLRP3-related inflammatory diseases.
The NLRP3 inflammasome is a key complex to process and secrete IL-1β in response to a large variety of stimuli. These stimuli, damage-associated and pathogen-associated molecular patterns (DAMPs and PAMPs), include particulate factors such as monosodium urate (MSU) crystals, basic calcium phosphate crystals, cholesterol crystals, and soluble factors such as nigericin and extracellular ATP 1 . Several reports have demonstrated that the NLRP3-IL-1β pathway is strongly associated with many diseases such as gouty attack, atherosclerosis and diabetic nephropathy [2] [3] [4] . Thus, the NLRP3-IL-1β pathway may be a potential target for the treatment of the related-inflammatory diseases.
Mitochondria generate ATP and act as signalling hubs for apoptosis, ROS production and calcium mobilization. Upon NLRP3 activation, mitochondria also play critical roles 5 . Mitochondrial damage results in decrease in intracellular NAD + , a cofactor for NAD + -dependent sirtuin 2, resulting in the accumulation of acetylated α-tubulin. Acetylated α-tubulin mediates the transport of mitochondria and subsequent colocalization of ASC on mitochondria to NLRP3 on the endoplasmic reticulum, leading to the activation of NLRP3 inflammasome 6 . In addition, mitochondrial ROS (mitoROS) activates MAVS on the outer membrane, which associates with NLRP3 and promotes its oligomerization 7 . Furthermore, mitochondrial membrane depolarization causes the translocation of cardiolipin from the inner membrane to the outer membrane. The recruitment and interaction of NLRP3
Immunoblot. Equal amounts of supernatants or cell lysates were loaded to SDS-PAGE, and immunoblot was performed by anti-cleaved IL-1β (Asp117) Ab (Cell Signaling Technology Inc., Danvers, MA), anti-Caspase-1 (p20) Ab (Casper-1, AdipoGen, San Diego, CA) or anti-NLRP3 Ab (D4D8T, Cell Signaling Technology Inc.).
ELISA.
For detection of IL-1β level in supernatant, mouse IL-1β ELISA kit (eBioscience, Inc., San Diego, CA) was used according to the manufacturer's instructions.
Measurement of mitochondrial ROS level. Mitochondrial ROS level was measured with dihydror-
hodamine 123 (DHR123, Thermo Fisher Scientific Inc.), which is a nonfluorescent ROS indicator that can passively diffuse across membranes where it is oxidized in the mitochondria to fluorescent rhodamine 123. Briefly, BMDMs in half area 96-well clear bottom black plate were primed, pretreated 30 min with vehicle, febuxostat or MitoTEMPO, and then stimulated 90 min with medium, nigericin or MSU. After stimulation, cells were loaded 30 min with 2 μM DHR123, and fluorescence intensity on 500 nm (excitation) and 536 nm (emission) was measured with fluorescence plate reader.
Measurement of LDH. LDH in supernatant was measured using CytoTox-ONE ™ Homogeneous
Membrane Integrity Assay (Promega) according to the manufacturer's instructions. LDH release (%) was calculated by using the following formula. LDH release (%) = [(value in sample) − (background)]/[(value in Triton X-100-treated sample) − (background)] × 100.
Measurement of cell viability. Cell viability was measured with double staining kit (Dojindo, Kumamoto, Japan) based on calcein-AM staining for live cells and propidium iodide (PI) staining for dead cells. Briefly, BMDMs plated in half area 96-well clear bottom black plate were prime, pretreated 30 min with vehicle, febuxostat or MitoTEMPO, and then stimulated 6 h with medium or nigericin. For dead cell preparation for positive control, cells were treated 1 min with ethanol (70%). After stimulation, cells were stained 15 min with 2 μM calcein-AM and 4 μM PI, and fluorescence intensities on 485 nm (excitation)/535 nm (emission) for calcein-AM and 530 nm (excitation)/620 nm (emission) for PI were measured with fluorescence plate reader.
Measurement of mitochondrial membrane potential. Mitochondrial membrane potential was measured with tetramethylrhodamine, ethyl ester (TMRE, Life Technologies), which is a fluorescent dye that is readily sequestered by active mitochondria depending on mitochondrial membrane potential. Depolarized or inactive mitochondria have decreased membrane potential and then fail to sequester TMRE. Briefly, BMDMs in 96-well half area clear bottom black plate were pretreated 30 min with vehicle, febuxostat or MitoTEMPO, and then Metabolome analysis. Primed BMDMs were pretreated 30 min with vehicle or febuxostat, and then stimulated 90 min with medium or nigericin. Cells were washed with 5% mannitol and the metabolites were extracted with methanol containing internal standard. The metabolites were analysed by CE-TOFMS (Agilent CE-TOFMS system) and CE-QqQMS (Agilent CE system and Agilent 6460 TripleQuad LC/MS). Absolute value of metabolite was determined, and the relative ratios of nigericin-treated group to medium group, and of febuxostat/ nigericin-treated group to nigericin-treated group were calculated to be expressed as the heat map. Statistical analysis. All data are expressed as mean ± SD. For two-group comparisons, student's t test was used. For multiple comparisons, one-way ANOVA followed by Tukey's test were used to compare between each groups. All data were statistically analyzed using GraphPad PRISM software version 6.01 (GraphPad, La Jolla, CA). Differences with a probability value of <0.05 were considered significant.
Measurement of mitochondrial respiration capacity. Primed BMDMs plated in Seahorse XFp

Results
Febuxostat inhibits IL-1β secretion by mitochondrial ROS-independent and -dependent mechanisms. We have previously demonstrated that macrophage secretion of IL-1β upon NLRP3 inflammasome activation involved mitoROS production by XOR. Accordingly, we found that pharmacological inhibition of XOR by febuxostat decreased mitoROS and IL-1β secretion 12 . Consistent with our previous study, febuxostat effectively inhibited IL-1β secretion by nigericin or MSU, depending on NLRP3, caspase-1 and ASC (Fig. 1a , and see Supplementary Fig. S1 ). The inhibitory effects of febuxostat on IL-1β secretion were also confirmed in human primary macrophages (see Supplementary Fig. S2 ). We provide now additional data showing that febuxostat also acts on mitoROS-independent mechanisms of IL-1β secretion. Nigericin-induced IL-1β secretion was largely www.nature.com/scientificreports www.nature.com/scientificreports/ independent of mitoROS production as the mitochondrial scavenger MitoTEMPO only had a minor inhibitory effect on nigericin-induced IL-1β secretion (Fig. 1b) . On the other hand, MitoTEMPO significantly inhibited MSU-induced IL-1β secretion (Fig. 1b) . Differential contribution of mitoROS in nigericin-and MSU-mediated cellular responses was also supported by the fact that nigericin was a poor inducer of mitoROS formation whereas MSU was a much stronger inducer (Fig. 1c) . MitoROS production by MSU was inhibited by both febuxostat and MitoTEMPO (Fig. 1c) , whereas as expected in nigericin-treated cells, febuxostat and MitoTEMPO did not change mitoROS levels. Altogether, these results suggested that upon nigericin treatment, febuxostat inhibits IL-1β secretion via a mechanism that is distinct from mitoROS suppression.
Febuxostat inhibits cell death in mitochondrial ROS-independent manner. We next examined the effects on cell death, because NLRP3 activators have been reported to disturb membrane integrity and induce cell death 13 . As shown in Fig. 2a , treatment for 2 h with nigericin led to significant increase in LDH release, indicating the disturbance of cell membrane integrity. In addition, longer treatment (6 h) caused cell death (Fig. 2b) . Febuxostat significantly suppressed nigericin-induced LDH release and cell death, whereas MitoTEMPO did not (Fig. 2a,b) . These results demonstrated that nigericin induces cell death, as well as IL-1β secretion, independently of mitoROS production, and that febuxostat protects cells from cell injury and death upon nigericin treatment. www.nature.com/scientificreports www.nature.com/scientificreports/ Febuxostat restored intracellular ATP levels and inhibited IL-1β secretion on NLRP3 inflammasome activation. We have previously shown that nigericin induces iATP loss, mitochondrial membrane potential (Δψm) depolarization, finally leading to IL-1β secretion, which is independent of mitROS production 14 . Thus, we examined the effects of febuxostat on iATP content and Δψm. Nigericin treatment caused approximately 60% decrease in iATP compared to non-treated control. Febuxostat prevented the lowering of iATP levels on nigericin treatment whereas MitoTEMPO failed to do so (Fig. 3a) . Similarly, febuxostat significantly protected nigericin-induced depolarization of Δψm and this effect was greater than that of MitoTEMPO (Fig. 3b) . As shown in Fig. 1a,b , febuxostat inhibited nigericin-induced IL-1β secretion in the same condition. Considering that iATP depletion induces Δψm depolarization, finally leading to IL-1β secretion in primed BMDMs 14 , these data suggested that restored iATP by febuxostat leads to the protection of Δψm depolarization and IL-1β secretion. We next examined whether febuxostat inhibits IL-1β secretion in artificial iATP depleting condition that febuxostat failed to increase iATP level (Fig. 3c) . In this condition, there was no effect of febuxostat on IL-1β secretion (Fig. 3d) , implying that the importance of restored iATP by febuxostat on IL-1β inhibition. Taken www.nature.com/scientificreports www.nature.com/scientificreports/ together, these data suggested that restored iATP by febuxostat contributes to Δψm maintenance and IL-1β inhibition. However, further studies are needed to clarify the detailed mechanisms.
Febuxostat restored intracellular ATP by activating the purine salvage pathway. To determine the mechanism underlying the restoration of iATP by febuxostat, we investigated the intracellular levels of purine metabolites. XOR acts at the final steps of the purine metabolism pathway. XOR inhibition leads to the accumulation of hypoxanthine, in turn resulting in the activation of the salvage pathway, a recycling pathway of purine bases to form the purine nucleotides (Fig. 4a) . Nigericin treatment led to the decreases in ATP, ADP, AMP and total adenylate (ATP + ADP + AMP), and an increase in uric acid level, indicating that nigericin induced purine catabolism. Febuxostat significantly inhibited the rise in uric acid, and restored ATP, ADP, AMP and total adenylate cell content (Fig. 4b) . In addition to the adenylate, GTP was also restored by febuxostat (see Supplementary  Fig. S3 ). These data demonstrated that febuxostat restores iATP by activating the purine salvage pathway.
Febuxostat improves cellular bioenergetics. We found that XOR inhibition by febuxostat affects purine metabolites, leading to change in adenylates (ATP, ADP, AMP), crucially involved in various cellular events. Thus, we hypothesized that febuxostat could extensively affect intracellular metabolites upon NLRP3 inflammasome activation. To examine this, metabolome analysis was performed using stimulated BMDMs treated 90 min with nigericin and/or febuxostat. Metabolome analysis revealed that nigericin perturbed various intracellular pathways: glycolysis, TCA cycle, glutaminolysis, pentose phosphate pathway, purine metabolism, nicotinamides, and glutathione metabolism (Fig. 5a) . Pyruvic acid and Acetyl CoA were increased by nigericin, suggesting that TCA cycle was stalled. Although uric acid levels were not increased in our metabolome analysis, upstream metabolites of uric acid, IMP and xanthine, were increased, suggesting that nigericin stimulates the purine degradation. Finally we could confirm by metabolome analysis that nigericin also induced down-regulation of adenylates (as found in Fig. 4b ). Most importantly, febuxostat treatment improved almost all of nigericin-induced changes of Basal respiration and ATP production were calculated by subtracting OCR value at 73.7 and at 34.3 min from OCR value at 14.6 min in (c), respectively. Data are shown as mean ± SD of four independent experiments in singlet. *p < 0.05, **p < 0.01. intracellular metabolites (Fig. 5a ). These effects of febuxostat may be due to improved cellular energetics such as restored iATP. Intermediate metabolites of TCA cycle, which are utilized for electron transport chain (ETC) followed by oxidative phosphorylation (OxPhos) in mitochondria, were increased by febuxostat (Fig. 5a) . Finally, we sought to determine whether febuxostat improves mitochondrial function. To this end we examined the mitochondrial respiratory capacity by measuring the oxygen consumption rate (OCR). Figure 5b illustrates the mitochondrial respiratory capacity followed by oligomycin (Oligo, ATP synthase inhibitor), FCCP (uncoupler) and antimycin/rotenone (AA/Ro, complex III/I inhibitor, respectively). Nigericin functions as K + /H + exchanger in mitochondria, thus leading to the disturbance of ETC. In nigericin-treated cells, basal respiration, ATP production, and maximal respiration were depleted compared with non-treated control cells (Fig. 5c ). Maximal respiration was not changed by febuxostat, suggesting that febuxostat is not a direct antagonist of nigericin. Febuxostat significantly restored the basal respiration and ATP production in nigericin-treated cells (Fig. 5d) . Collectively, these results demonstrated that febuxostat improves mitochondrial function and cellular bioenergetics.
Discussion
NLRP3 inflammasome activation leads to IL-1β secretion by multiple mechanisms, one of which is on mitoROS production 15, 16 . We have previously shown that XOR inhibition attenuated IL-1β release by reducing ROS generation 12 . Here we show that febuxostat, a potent XOR inhibitor, reduced IL-1β secretion by both mitoROS-dependent and independent pathways. Febuxostat restored iATP levels and improved mitochondrial dysfunction in nigericin-treated cells. Cellular bioenergetics were also improved.
Changes of cellular bioenergetics have been reported to be involved in IL-1β secretion during NLRP3 activation [17] [18] [19] . In this study, febuxostat improved nigericin-induced disturbance of cellular bioenergetics. This was supported by the findings that iATP was restored by febuxostat and that the metabolites of glycolysis and TCA cycle was increased by febuxostat (Figs. 3a, 4b and 5a ). Metabolomic analysis using plasma from XOR knockout mice revealed that intermediates of TCA cycle such as pyruvate, citrate, aconirate, α-ketoglutarate, fumarate and malate were up-regulated compared to wild-type mice 20 . In addition, febuxostat up-regulates the expression of glutamate oxaloacetate transaminase 2, which converts glutamate to α-ketoglutarate, in spinal cords from experimental autoimmune encephalomyelitis mice 21 . Thus, XOR inhibition improved cellular bioenergetics. The purine salvage pathway plays an important role in ATP maintenance, as evidenced by the low levels of ATP in Lesch-Nyhan syndrome patients who have a mutation of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), a crucial enzyme in the salvage pathway 22 . XOR inhibition results in the accumulation of hypoxanthine, which in turn leads to the activation of salvage pathway via HGPRT 23, 24 . Given these previous reports, the restoration of iATP by febuxostat is mainly due to the activation of salvage pathway because febuxostat increased not only ATP but also GTP (see Supplementary Fig. S3 ). In addition, OxPhos in mitochondria may also contribute the restoration of iATP because Oligo-sensitive ATP production was increased by febuxostat (Fig. 5d) . ATP synthase phosphorylates ADP resulting in ATP production. Thus, increased ADP supply by XOR inhibition may cause ATP production in mitochondria.
The mechanism involved in the induction of the purine salvage pathway by febuxostat is linked to its high specificity for XOR. Febuxostat is a non-purine XOR inhibitor which does not affect HGPRT activity 25 . The accumulation of hypoxanthine by febuxostat induces the production of IMP via HGPRT activity. We also studied the www.nature.com/scientificreports www.nature.com/scientificreports/ effect of a purine analogue XOR inhibitor, allopurinol. Allopurinol, a hypoxanthine isomer, by its chemical structure could also act as a competitive inhibitor of HGPRT 26, 27 . Indeed, in macrophages allopurinol did not restore decreased intracellular levels of ATP induced by nigericin, strongly suggesting that the purine salvage pathway is inhibited by allopurinol (see Supplementary Fig. S4 ).
Mitochondria dysfunction is major event mediating NLRP3 activation and subsequent IL-1β secretion 15, 16 . It has been reported that mitochondrial damage leads to a decrease in intracellular NAD + , which in turn results in the inactivation of NAD + -dependent sirtuin 2, the accumulation of acetylated α-tubulin, the transport of mitochondria, and finally the activation of NLRP3 6 . Consistent with this report, intracellular NAD + was significantly decreased by nigercin. Interestingly, febuxostat significantly restored NAD + level. In addition, NAD + replenishment inhibited nigericin-induced IL-1β secretion and restored iATP levels (see Supplementary Fig. S5 ). These results suggest that the restoration of iATP and NAD + by XOR inhibition is likely to modulate the various events in mitochondria upon NLRP3 activation. However, further studies are needed to understand the detailed mechanisms.
In conclusion, we have showed that XOR inhibition by febuxostat attenuates IL-1β secretion in activated macrophages (Fig. 6 ). In the case of stimuli with mitoROS production, such as MSU crystals, the inhibitory effect on IL-1β is mainly mediated by inhibition of mitoROS production. In stimuli which do not induce mitoROS production, such as nigericin, restored iATP and improved mitochondrial function play important roles. Our findings suggest the importance of cellular bioenergetics in regulating NLRP3 activation, and the promising option of XOR inhibition in controlling inflammatory diseases.
